Growth hormone secretagogue: difference between revisions
Diff·revision 1 → 2·03:08, 2 Nov 2024
Difference between revision 1 and revision 2 of Growth hormone secretagogue. 5 lines changed; the page grew by 603 bytes.
| Revision 1 — 21:38, 25 Oct 2024 SPPS_Sorrel (talk) new article: research peptide, expansion welcome 1,239 bytes +1,239 | Revision 2 — 03:08, 2 Nov 2024 SafetySignalSid (talk) split the pharmacology section from the marketing history 1,842 bytes +603 | ||
|---|---|---|---|
| 11 | GHRH analogues — [[Sermorelin|sermorelin]], [[CJC-1295|CJC-1295]], [[Tesamorelin|tesamorelin]] — mimic the hypothalamic releasing hormone. Ghrelin-receptor agonists such as [[Ipamorelin|ipamorelin]] act at a separate receptor and by a partly complementary mechanism.{{r|sigalos2018}} | 11 | GHRH analogues — [[Sermorelin|sermorelin]], [[CJC-1295|CJC-1295]], [[Tesamorelin|tesamorelin]] — mimic the hypothalamic releasing hormone. Ghrelin-receptor agonists such as [[Ipamorelin|ipamorelin]] act at a separate receptor and by a partly complementary mechanism.{{r|sigalos2018}} |
| 12 | 12 | ||
| + | 13 | == Mechanisms == | |
| + | 14 | GHRH-receptor agonism at somatotroph cells raises cAMP and promotes synthesis and release of growth hormone. Native GHRH has a very short half-life; the analogues are modified to extend it, and [[CJC-1295|CJC-1295]] uses a linker permitting covalent binding to albumin for a much longer duration.{{r|sigalos2018}} | |
| + | 15 | ||
| + | 16 | Ghrelin-receptor agonism acts through a different pathway and also suppresses somatostatin tone, so the two mechanisms combine more than additively in some experimental settings — the rationale for combining them that appears in community discussion.{{r|sigalos2018}} | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |